VYNE Therapeutics (VYNE)
NASDAQ:VYNE
Want to see VYNE full AI Analyst Report?
Top Page
VYNE Therapeutics
(NASDAQ:VYNE)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.68
▲(16.72% Upside)
Action:Reiterated
Date:05/22/26
The score is held down primarily by very weak financial performance (small/declining revenue, large ongoing losses, and continued cash burn). Technicals are moderately supportive with the stock above major moving averages, but overbought signals add near-term risk. Corporate events are mixed, with pipeline/merger optionality offset by Nasdaq compliance concerns; valuation remains constrained by negative earnings.
Positive Factors
Very low leverage / minimal debt
Minimal debt materially reduces interest and refinancing risk, preserving strategic optionality while the company executes R&D and potential M&A. With ongoing cash burn, a low-debt base buys time for financing or partnership solutions without immediate solvency stress.
Negative Factors
Persistent negative free cash flow
Sustained negative free cash flow forces recurrent financing or dilutive transactions, constraining long-term flexibility. Continued cash burn relative to negligible revenues limits the company’s ability to self-fund development, increasing execution and dilution risk absent partner funding or successful asset monetization.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / minimal debt
Minimal debt materially reduces interest and refinancing risk, preserving strategic optionality while the company executes R&D and potential M&A. With ongoing cash burn, a low-debt base buys time for financing or partnership solutions without immediate solvency stress.
Read all positive factors
VYNE Therapeutics (VYNE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.68M
Dividend YieldN/A
Average Volume (3M)2.75M
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-24.96%
EPS Growth46.11%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding33,352,860
10 Day Avg. Volume3,707,448
30 Day Avg. Volume2,746,500
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.89
Price to Sales (P/S)43.53
P/FCF Ratio-0.75
Enterprise Value/Market Cap-0.58
Enterprise Value/Revenue-29.04
Enterprise Value/Gross Profit-29.43
Enterprise Value/Ebitda0.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.59
Revenue Forecast (FY)N/A
VYNE Therapeutics Business Overview & Revenue Model
Company Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials ...
How the Company Makes Money
null...
VYNE Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 454.00K | 570.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| Gross Profit | 448.00K | 547.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| EBITDA | -24.35M | -26.73M | -43.63M | -29.26M | -34.22M | -38.80M |
| Net Income | -21.46M | -26.48M | -39.83M | -28.45M | -23.21M | -73.33M |
Balance Sheet | ||||||
| Total Assets | 25.87M | 30.16M | 66.91M | 97.69M | 40.76M | 67.05M |
| Cash, Cash Equivalents and Short-Term Investments | 24.93M | 29.01M | 61.52M | 93.25M | 30.91M | 42.25M |
| Total Debt | 0.00 | 0.00 | 99.00K | 214.00K | 0.00 | 349.00K |
| Total Liabilities | 1.24M | 2.40M | 14.82M | 8.95M | 9.56M | 18.41M |
| Stockholders Equity | 24.64M | 27.77M | 52.09M | 88.73M | 31.20M | 48.64M |
Cash Flow | ||||||
| Free Cash Flow | -25.74M | -33.12M | -34.09M | -25.34M | -29.20M | -56.37M |
| Operating Cash Flow | -25.74M | -33.12M | -33.97M | -25.34M | -29.20M | -56.37M |
| Investing Cash Flow | 22.24M | 37.37M | 23.36M | -57.35M | 15.67M | 1.03M |
| Financing Cash Flow | -71.00K | -143.00K | -141.00K | 82.39M | 1.65M | 39.78M |
VYNE Therapeutics Technical Analysis
Positive
0.58
Price Trends
0.64
Positive
0.61
Positive
0.49
Positive
Market Momentum
0.01
Positive
71.65
Negative
95.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Positive. The current price of 0.58 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.64, and above the 200-day MA of 0.49, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 71.65 is Negative, neither overbought nor oversold. The STOCH value of 95.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VYNE.
VYNE Therapeutics Risk Analysis
VYNE Therapeutics disclosed 85 risk factors in its most recent earnings report. VYNE Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
VYNE Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $22.68M | -1.37 | -74.15% | ― | -24.96% | 46.11% | |
50 Neutral | $137.85M | -2.48 | -116.86% | ― | -98.25% | 76.83% | |
50 Neutral | $17.72M | -0.41 | -189.72% | ― | ― | 80.68% | |
49 Neutral | $7.06M | -3.16 | -60.33% | ― | 23.52% | 48.34% | |
41 Neutral | $43.31M | -0.95 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
VYNE
VYNE Therapeutics
0.69
-0.28
-28.91%
KZIA
Kazia Therapeutics
12.67
8.89
235.19%
XBIO
Xenetic Biosciences
3.08
0.10
3.36%
KALA
KALA BIO
2.29
-189.71
-98.81%
INAB
IN8bio
1.80
-2.80
-60.89%
VYNE Therapeutics Corporate Events
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline
Positive
May 21, 2026
On May 21, 2026, Yarrow Bioscience published an investor presentation outlining its strategy and clinical plans, which VYNE Therapeutics in turn made available via its investor website as part of broader disclosure tied to their proposed reverse m...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance
Negative
Mar 12, 2026
On September 12, 2025, VYNE Therapeutics disclosed that it had fallen out of compliance with Nasdaq’s $1.00 minimum bid price requirement after its shares traded below that threshold for 30 consecutive business days and was given until March...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.